川宁生物 reported revenue of ¥2.10B for the period ended 2026-06-30, -10.7% year on year. Net income was ¥0.27B, a 13.1% net margin on a 26.3% gross margin. The largest revenue line is 医药中间体 at 88% of the total. Free cash flow for the period was ¥0.58B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.10B | -10.7% |
| Gross profit | ¥0.55B | — |
| Operating income | ¥0.34B | — |
| Net income | ¥0.27B | -39.7% |
| Gross margin | 26.3% | Net margin 13.1% |
| Revenue Q/Q | -8.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 医药中间体 | ¥1.84B | 87.6% |
| 其他(补充) | ¥0.15B | 7.2% |
| 其他主营业务 | ¥0.11B | 5.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.55B | 73.7% |
| R&D | ¥0.04B | 1.9% |
| SG&A | ¥0.10B | 4.9% |
| Tax & other | ¥0.07B | 3.3% |
| Item | Amount |
|---|---|
| Total assets | ¥10.33B |
| Total liabilities | ¥2.33B |
| Shareholders' equity | ¥8.01B |
| Equity / assets | 77.5% |
| Operating cash flow | ¥0.59B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.58B |
| Cash conversion (OCF / net income) | 283% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
华如科技 ・ 真兰仪表 ・ 朗坤科技 ・ 西测测试 ・ 美利信 ・ 万得凯 ・ 鑫宏业 ・ 昆船智能 ・ 智立方 ・ 凡拓数创 ・ 科瑞思 ・ 威士顿
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies